Business Wire

ADVA

Share
POST Luxembourg uses ADVA’s optical cesium atomic clock to combat GNSS attacks and improve PNT resilience

ADVA (FSE: ADV) today announced that POST Luxembourg has deployed ADVA’s Oscilloquartz optical cesium atomic clock to protect its GNSS-based timing network from jamming and spoofing cyberattacks. The country’s leading provider of ICT and telecom services is utilizing the aPNT+ technology to meet the synchronization requirements of 5G mobile connectivity and next-generation enterprise cloud applications. With its high availability and unrivaled holdover, the optical cesium atomic clock solution ensures the accuracy and stability needed for the most stringent telecom applications. The solution integrated easily into POST Luxembourg’s existing network management system and is remotely controlled and assured by the ADVA Ensemble Controller with Sync Director.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005303/en/

“With this deployment, we’re injecting new levels of precision, stability, resiliency and holdover into our synchronization network. It’s an important step as we look to meet stricter timing requirements driven by emerging applications. ADVA’s Oscilloquartz optical cesium atomic clock empowers us to support our enterprise customers as they harness new industry digitalization opportunities. It’s also a key tool as we move into the next phase of 5G mobile provision,” said Pierre Scholtes, head of telecom networks, POST Luxembourg. “In recent years, we’ve developed a very strong relationship with ADVA’s team. When it came to enhancing and protecting our timing infrastructure for the future, that mutual trust and close support was just as important as the capabilities and performance of ADVA’s technology.”

ADVA’s coreSync OSA 3350 ePRC+ is now enabling POST Luxembourg to outperform even the most stringent recommendations for the precision and stability of frequency, phase and time. Deployed in the core of the service provider’s timing network, it’s the ideal backup for satellite-based synchronization and the best defense against GNSS jamming and spoofing attacks. The coreSync OSA 3350 ePRC+ is the first commercial optical cesium atomic clock specifically designed for ePRC applications that require outstanding stability and resiliency. It offers enhanced holdover compared with standard magnetic cesium clocks. When combined with an OSA grandmaster clock combiner solution to create an enhanced primary reference time clock (ePRTC) system, it provides holdover stability under 35ns for more than 14 days. This is significantly better than the ITU ePRTC specification, which requires no more than 70ns from UTC after a 14-day period.

“Our market-first optical cesium atomic clock is now delivering phenomenal holdover and protecting timing integrity throughout POST Luxembourg’s network. For customers across the Benelux region, it opens the door to a world of new applications that require extremely high reliability as well as very low latency,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Complementing satellite-based synchronization solutions with ultra-stable atomic clocks is the best available way to safeguard against GNSS vulnerabilities and meet new requirements for precision and availability. POST Luxembourg is once again leading the way in Europe by adopting the most advanced innovation so it can continue to outperform customer expectations.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye